Drs. Rotem Gura-Sadovsky and Maayan Eilon-Ashkenazy explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.
This article answers the question: what if, instead of relying on systemic delivery, we could create a platform that anchors drugs directly at the site of need and controls its release over weeks or months?
Thanks to the pioneering work of researchers advancing our knowledge of basic science and cancer, the field has been able to transform the lives of millions of patients with CML. But challenges remain, and everyone in the industry strives to improve upon the “miracle drug” imatinib, that was approved almost 25 years ago.
Join Dr. Masumi Dave, Application Lab Manager at Gattefossé USA, for a practical, step-by-step guide to developing optimized Self-Emulsifying Drug Delivery Systems (SEDDS). This webinar provides a proven framework you can apply in your lab to overcome solubility and permeability challenges with lipid excipients.
In this exclusive interview, Latham shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success that balances both scientific rigor and therapeutic optimism.
Dr. Susan Billings, Chief Commercial Officer of Resilience, discusses pressing issues in the CDMO space, the opportunities driving innovation, and how her company is shaping the future of drug substance and drug product manufacturing.
Sebastian Stenderup, Executive Director, Head of Commercial EMEA, Lonza, discusses some of the trends CDMOs are currently facing, from the growth of ADCs to the importance of sustainability, and how his company is responding to them.
Vetter’s leadership discusses the company’s vision for strategic restructuring, their insights on Contract Development and Manufacturing trends in 2025, and what this strategic change means for the sustainable growth of the company and its global expansion.
Anshul Gupte, PhD, RAC Drugs, VP of Pharmaceutical Development at PCI Pharma Services, talks about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
Steven Facer, Senior Vice President of Sales and Marketing at Adare Pharma Solutions, shares practical insights on what makes CDMO partnerships work and what can cause them to fall short.
Chris Gilmor, Vice President of Sales, Sanner of America, explains how Sanner’s Advance with Agility™ program helps its partners achieve faster development times and reduce time to market, and how the company embeds sustainable practices into its global business.
Jacob Hunter, Chief Business Officer, ALZpath, Inc., discusses the development and deployment of the company’s proprietary pTau217 antibody, bridging the gap between detection and treatment to improve patient outcomes globally.
Lew Bender, Founder and CEO of Intensity Therapeutics, discusses the company’s science, clinical program, the drug development process, and more.
COMPANY PROFILE
ProMed Pharma is your distinguished development partner in long-acting injectable and implantable dosage forms. With nearly 20 years of operational history, we have honed our expertise in polymer-based dosage forms, achieving mastery in extended-release dosing. Our proficiency spans molding, extrusion, and microencapsulation techniques, leveraging a diverse spectrum of polymeric excipients encompassing silicones, thermoplastics, and biodegradables. At ProMed Pharma, our commitment to rapid project execution is underpinned by a steadfast dedication to scientific inquiry and technical finesse. Whether you represent an emerging biotech venture or a global pharmaceutical entity, entrust us as your CDMO partner, as we diligently translate scientific concepts into finished dosage forms. Click here for more.
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …
The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …
CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …
Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
December 17 – Lyophilization Manufacturing
January 7 – Capsules